Effect of Intravenous Lidocaine on Serum Interleukin-17 After Video-Assisted Thoracic Surgery for Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

A phase II/III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced Non-Small Cell Lung Cancer (NSCLC)

http://isrctn.org/> ◽

10.1186/isrctn77341241 ◽

2012 ◽

Author(s):

Siow Ming Lee

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽

ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.

10.1200/jco.2010.28.15_suppl.7631 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7631-7631 ◽

Cited By ~ 11

Author(s):

M. Schuster ◽

J. R. Rigas ◽

S. V. Orlov ◽

B. Milovanovic ◽

K. Prabhash ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽

NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

10.1200/jco.2014.32.15_suppl.8036 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8036-8036 ◽

Cited By ~ 6

Author(s):

Peter Michael Ellis ◽

Geoffrey Liu ◽

Michael Millward ◽

Francesco Perrone ◽

Frances A. Shepherd ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Prior Chemotherapy ◽

Egfr Tki

A randomised phase II double blind placebo controlled trial of Whole Brain RadioTherapy (WBRT) and Tarceva (OSI-774, erlotinib) in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with multiple brain metastases

http://isrctn.org/> ◽

10.1186/isrctn31916843 ◽

2012 ◽

Author(s):

Siow Ming Lee

Keyword(s):

Lung Cancer ◽

Brain Metastases ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Whole Brain Radiotherapy ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Brain Radiotherapy

P-238 Fatigue and plasma cytokines in a randomized double-blind placebo-controlled trial of epoetin alfa in patients undergoing combined modality therapy for unresetable non-small cell lung cancer (NSCLC)

Lung Cancer ◽

10.1016/s0169-5002(03)92207-0 ◽

2003 ◽

Vol 41 ◽

pp. S151-S152 ◽

Cited By ~ 2

Author(s):

Wendye M. DiSalvo ◽

Virginia L. Beggs ◽

Louise P. Meyers ◽

Konstantin H. Dragnev ◽

Jennifer J. Gibson ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Combined Modality Therapy ◽

Small Cell ◽

Epoetin Alfa ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Plasma Cytokines

C1-03: A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283190.70038.e9 ◽

2007 ◽

Vol 2 (8) ◽

pp. S359 ◽

Cited By ~ 3

Author(s):

Siow-Ming Lee ◽

Penella J. Woll ◽

Robin M. Rudd ◽

Nicole H. Gower ◽

Christian H. Ottensmeier ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(16)32022-0 ◽

2016 ◽

Vol 388 ◽

pp. S95 ◽

Cited By ~ 4

Author(s):

Rui Zhang ◽

Zhi-Yu Wang ◽

Yue-Hua Li ◽

Yao-Hong Lu ◽

Shuai Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Dynamic Contrast Enhanced ◽

Contrast Enhanced ◽

Contrast Enhanced Mri

Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-0483 ◽

2018 ◽

Vol 24 (17) ◽

pp. 4089-4097 ◽

Cited By ~ 22

Author(s):

Tadashi Akiba ◽

Toshiaki Morikawa ◽

Makoto Odaka ◽

Takeo Nakada ◽

Noriki Kamiya ◽

...

Keyword(s):

Lung Cancer ◽

Vitamin D ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Vitamin D Supplementation ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽

Double blind, placebo controlled trial of oral lactoferrin in combination therapy for first line non-small cell lung cancer (NSCLC)

10.1200/jco.2005.23.16_suppl.7141 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 7141-7141

Author(s):

Y. Wang ◽

E. Yankee ◽

A. Varadhachary

Keyword(s):

Lung Cancer ◽

Combination Therapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Randomized, double-blind, placebo-controlled trial of evofosfamide (Evo) and pemetrexed (Pem) in advanced non-squamous non-small cell lung cancer (n-s NSCLC).

10.1200/jco.2016.34.15_suppl.9075 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9075-9075

Author(s):

Tibor Csõszi ◽

Jonathan Wade Goldman ◽

Maria Szilasi ◽

Joachim Von Pawel ◽

Silvia Novello ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽